A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer

Trial Profile

A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Feb 2017

At a glance

  • Drugs Veliparib (Primary) ; Gemcitabine
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions
  • Acronyms VelGemRad
  • Most Recent Events

    • 25 Aug 2016 Status changed from recruiting to active, no longer recruiting.
    • 30 Mar 2016 Planned End Date changed from 1 Jul 2019 to 1 Jul 2018 as per ClinicalTrials.gov record.
    • 30 Mar 2016 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top